Immunological impact of an additional early measles vaccine in Gambian children: Responses to a boost at 3 years

Vaccine

Volumn 30, Issue 15, 2012, Pages 2543-2550

  Njie Jobe, Jainaba ^a   Nyamweya, Samuel ^a   Miles, David J C ^a   van der Sande, Marianne ^b,c   Zaman, Syed ^d   Touray, Ebrima ^a   Hossin, Safayet ^a   Adetifa, Jane ^a   Palmero, Melba ^e   Burl, Sarah ^f   Jeffries, David ^a   Rowland Jones, Sarah ^g   Flanagan, Katie ^a   Jaye, Assan ^a   Whittle, Hilton ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Adventist Health Ministries   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibody; Booster dose; Cellular immunity; Measles vaccine; Two dose schedule

Indexed keywords

GAMMA INTERFERON; MEASLES VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; GAMBIA; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TREATMENT OUTCOME;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GAMBIA; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; INTERFERON-GAMMA; MEASLES; MEASLES VACCINE; MEASLES VIRUS; T-LYMPHOCYTES;

EID: 84858285682     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.083     Document Type: Article

References (34)

1. EPI The optimal age for measles immunization. Wkly Epidemiol Rec 1982, 57:89-91.
2. Papania M., Baughman A.L., Lee S., Cheek J.E., Atkinson W., Redd S.C., et al. Increased susceptibility to measles in infants in the United States. Pediatrics 1999, 104:e59.
3. Otten M., Kezaala R., Fall A., Masresha B., Martin R., Cairns L., et al. Public-health impact of accelerated measles control in the WHO African Region 2000-03. Lancet 2005, 366:832-839.
4. Garly M.L., Martins C.L., Bale C., da Costa F., Dias F., Whittle H., et al. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy. Int J Epidemiol 1999, 28:347-352.
5. Martins C.L., Garly M.L., Bale C., Rodrigues A., Ravn H., Whittle H.C., et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008, 337:a661.
6. Aaby P., Martins C.L., Garly M.L., Bale C., Andersen A., Rodrigues A., et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ 2010, 341:c6495.
7. Garly M.L., Bale C., Martins C.L., Monteiro M., George E., Kidd M., et al. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 2001, 19:1951-1959.
8. Dilraj A., Cutts F.T., de Castro J.F., Wheeler J.G., Brown D., Roth C., et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 2000, 355:798-803.
9. Gans H.A., Yasukawa L.L., Alderson A., Rinki M., DeHovitz R., Beeler J., et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004, 190:83-90.
10. Hutchins S.S., Dezayas A., Le Blond K., Heath J., Bellini W., Audet S., et al. Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol 2001, 154:1064-1071.
11. van der Sande M.A., Kaye S., Miles D.J., Waight P., Jeffries D.J., Ojuola O.O., et al. Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS One 2007, 2:e492.
12. Samb B., Aaby P., Whittle H.C., Seck A.M., Rahman S., Bennett J., et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995, 14:203-209.
13. Whittle H.C., Campbell H., Rahman S., Armstrong J.R. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet 1990, 336:1046-1048.
14. Miles D.J., Sanneh M., Holder B., Crozier S., Nyamweya S., Touray E.S., et al. Cytomegalovirus infection induces T-cell differentiation without impairing antigen-specific responses in Gambian infants. Immunology 2008, 124:388-400.
15. Jaye A., Magnusen A.F., Sadiq A.D., Corrah T., Whittle H.C. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J Clin Invest 1998, 102:1969-1977.
16. Permar S.R., Klumpp S.A., Mansfield K.G., Carville A.A., Gorgone D.A., Lifton M.A., et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis 2004, 190:998-1005.
17. Stittelaar K.J., de Swart R.L., Vos H.W., van Amerongen G., Sixt N., Wild T.F., et al. Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine 2002, 20:2022-2026.
18. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21:3406-3412.
19. Samb B., Aaby P., Whittle H., Seck A.M., Simondon F. Decline in measles case fatality ratio after the introduction of measles immunization in rural Senegal. Am J Epidemiol 1997, 145:51-57.
20. Whittle H.C., Aaby P., Samb B., Jensen H., Bennett J., Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999, 353:98-102.
21. Lievano F.A., Papania M.J., Helfand R.F., Harpaz R., Walls L., Katz R.S., et al. Lack of evidence of measles virus shedding in people with inapparent measles virus infections. J Infect Dis 2004, 189(Suppl. 1):S165-S170.
22. Ward B.J., Griffin D.E. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin Immunol Immunopathol 1993, 67:171-177.
23. Gans H.A., Maldonado Y., Yasukawa L.L., Beeler J., Audet S., Rinki M.M., et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999, 162:5569-5575.
24. Selin L.K., Varga S.M., Wong I.C., Welsh R.M. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998, 188:1705-1715.
25. Whelan K.T., Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One 2009, 4:e5934.
26. Premenko-Lanier M., Rota P.A., Rhodes G., Verhoeven D., Barouch D.H., Lerche N.W., et al. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology 2003, 307:67-75.
27. Yu X.L., Cheng Y.M., Shi B.S., Qian F.X., Wang F.B., Liu X.N., et al. Measles virus infection in adults induces production of IL-10 and is associated with increased CD4+ CD25+ regulatory T cells. J Immunol 2008, 181:7356-7366.
28. Ovsyannikova I.G., Reid K.C., Jacobson R.M., Oberg A.L., Klee G.G., Poland G.A. Cytokine production patterns and antibody response to measles vaccine. Vaccine 2003, 21:3946-3953.
29. van Binnendijk R.S., Poelen M.C., Kuijpers K.C., Osterhaus A.D., Uytdehaag F.G. The predominance of CD8+ T cells after infection with measles virus suggests a role for CD8+ class I MHC-restricted cytotoxic T lymphocytes (CTL) in recovery from measles. Clonal analyses of human CD8+ class I MHC-restricted CTL. J Immunol 1990, 144:2394-2399.
30. Jaye A., Magnusen A.F., Whittle H.C. Human leukocyte antigen class I- and class II-restricted cytotoxic T lymphocyte responses to measles antigens in immune adults. J Infect Dis 1998, 177:1282-1289.
31. WHO position on measles vaccines. Vaccine 2009, 27:7219-7221.
32. Heymann D.L., Fine P.E., Griffiths U.K., Hall A.J., Mounier-Jack S. Measles eradication: past is prologue. Lancet 2010, 376:1719-1720.
33. Unger J.P., De Paepe P., Green A. A code of best practice for disease control programmes to avoid damaging health care services in developing countries. Int J Health Plann Manage 2003, 18(Suppl. 1):S27-S39.
34. Helfand R.F., Witte D., Fowlkes A., Garcia P., Yang C., Fudzulani R., et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008, 198:1457-1465.